Project description:Cleavage factor I mammalian (CFIm) complex, composed of cleavage and polyadenylation specificity factor CPSF6, regulates alternative polyadenylation (APA). CPSF6 has a RS-like domain which plays role in protein -protein interactions. This interaction might have role in alternative polyadenylation site selection. The phosphorylation of RS- like domain might play role in protein -protein interaction and thus might have a role in alternative polyadenylation site selection. So we did mass specteroanalysis to analyse phosphorylation sites of RS-like domain of CPSF6.
Project description:Progressive Supranuclear Palsy–Richardson Syndrome (PSP-RS) is a rare, rapidly progressive neurodegenerative tauopathy frequently misdiagnosed as Parkinson’s Disease (PD) due to overlapping clinical features. The lack of reliable molecular biomarkers for early and differential diagnosis presents a major clinical challenge. To address this, we developed human midbrain organoids from induced pluripotent stem cells (iPSCs) derived from patients with sporadic PSP-RS, PD, and healthy controls (HCs), and profiled microRNA (miRNA) expression dynamics using small RNA sequencing. These 3D organoid models faithfully recapitulate key pathological hallmarks, including tau hyperphosphorylation in PSP-RS and Lewy body–like α-synuclein inclusions in PD. Our analysis revealed temporally dynamic, disease-specific miRNA signatures: miR-5683, miR-873-5p, miR-219b-5p, and miR-219a-2- 3p were selectively upregulated in PSP-RS, whereas PD organoids showed increased levels of miR-1-3p, miR-133b, miR-10b-5p, and miR-199a-5p. Additionally, miR-5683, miR-3085- 3p, miR-138-2-3p, and miR-124-3p emerged as key discriminators between PSP-RS and HCs. These findings highlight the utility of iPSC-derived midbrain organoids as a translationally relevant platform to uncover disease-specific regulatory networks and identify candidate miRNA biomarkers for atypical parkinsonian syndromes.
Project description:Human patients carrying genetic mutations in RBM20 develop a clinically aggressive dilated cardiomyopathy (DCM) characterized by early onset heart failure, high mortality, and sudden death, which is recapitulated in animal models. RBM20 has two primary domains, an RNA recognition motif (RRM) that binds RNA and an arginine/serine (RS)-rich domain that mediates spliceosome assembly and nuclear localization. Reported data showed that mutations in the RS domain lead to severe DCM. Loss of the RRM domain in RBM20 has been shown to disrupt the splicing of RBM20 target transcripts but does not lead to DCM. The objectives of the present study were to determine the functional role of the RS domain in DCM and examine the mechanisms. Mice expressing RBM20 lacking the RS domain (Rbm20ΔRS) were generated using CRISPR/Cas9 technology. Male and female Rbm20ΔRS mice developed a DCM-like phenotype characterized by ventricular dilation and impaired systolic function, that is more severe in females. Splicing of RBM20 target genes, including Ttn, was disrupted in both Rbm20ΔRS and Rbm20ΔRRM mice. However, RBM20 was mis-localized to the sarcoplasm only in the hearts of Rbm20ΔRS mice, indicating that mis-localization of RBM20 rather than disrupted splicing is key in DCM pathogenesis.